Logo
x

Search

Subscribe Now

 breast cancer

Daiichi Sankyo and AstraZeneca Receives the US FDA Approval for Datroway (Datopotamab Deruxtecan-dlnk) to Treat HR+/HER2- Metastatic Breast Cancer

Daiichi Sankyo and AstraZeneca Receives the US FDA Approval for Datroway (Datopotamab Deruxtecan-dlnk) to Treat HR+/HER2- Metastat...

  • January 20, 2025
ScreenPoint Medical Reports the Acquisition of Biomediq, Bolstering its Breast Cancer Risk Evaluation Capabilities

ScreenPoint Medical Reports the Acquisition of Biomediq, Bolstering its Breast Cancer Risk Evaluation Capabilities

  • January 9, 2025
Daiichi Sankyo’s Datroway Receives the MHLW’s Approval for Unresectable or Recurrent HR+/HER2- Breast Cancer

Daiichi Sankyo’s Datroway Receives the MHLW’s Approval for Unresectable or Recurrent HR+/HER2- Breast Cancer

  • December 27, 2024
Accent Therapeutics Receives the US FDA’s IND Approval of ATX-559 for Treating Breast Cancer

Accent Therapeutics Receives the US FDA’s IND Approval of ATX-559 for Treating Breast Cancer

  • October 25, 2024
Daiichi Sankyo Reports the sNDA Submission of Enhertu to Treat HER2 Low or Ultralow Metastatic Breast Cancer in Japan

Daiichi Sankyo Reports the sNDA Submission of Enhertu to Treat HER2 Low or Ultralow Metastatic Breast Cancer in Japan

  • October 4, 2024
Key Biosimilars Events of September 2024

Key Biosimilars Events of September 2024

  • October 4, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2025 PharmaShots - All Rights Reserved.